Uncertainty and constraints for pharma as the XEVMPD submission mandate nears in the EU
This article was originally published in SRA
Executive Summary
Andrew Marr, Erick Gaussens and Philippe Banes analyze the debate at a recent roundtable meeting in which drug companies aired their concerns over meeting the new requirements of the extended Eudravigilance Medicinal Product Dictionary.